Background/Aims: High-mobility group box 1 (HMGB1) elicits inflammatory responses through interactions with the receptor for advanced glycation end products (RAGE) and tolllike receptor 4 (TLR4). We investigated how RAGE and TLR4 expressions are regulated after HMGB1 stimulation in cultured human aortic endothelial cells (HAECs). Methods: RAGE and TLR4 expressions were analyzed by Western blot analysis and immunofluorescence staining. A disintegrin and metalloprotease 17 (ADAM17) activity was measured using a fluorogenic substrate. Results: Upon treatment with HMGB1, both RAGE and TLR4 began to decrease in cell lysate and remained decreased up to 24 h. The decrease in cellular RAGE and TLR4 was accompanied by an increase of N-terminal fragment of RAGE and TLR4 in culture supernatant, indicating ectodomain shedding of the receptors. HMGB1 activated p38 mitogen-activated protein kinase (p38 MAPK) and ADAM17, while HMGB1-induced ADAM17 activation was inhibited by SB203580, a p38 MAPK inhibitor. HMGB1-induced ectodomain shedding of RAGE and TLR4 was prevented by siRNA depletion of ADAM17 as well as TAPI-2, an inhibitor of ADAM family, and SB203580. HMGB1 pretreatment abolished p38 MAPK activation in response to 2nd HMGB1 stimulation. In the cells depleted of ADAM17, HMGB1-induced p38 MAPK activation was prolonged. siRNA depletion of RAGE, but not TLR4, suppressed HMGB1-induced p38 MAPK activation. Conclusion: In response to HMGB1 stimulation, HAECs rapidly undergo ectodomain shedding of RAGE and TLR4, and thereby become insensitive to further HMGB1 stimulation. ADAM17, activated through RAGE-p38 MAPK pathway, is implicated in the ectodomain cleavage of the receptors.
Introduction
High-mobility group box 1 (HMGB1) is a protein in the nucleus where it organizes DNA and regulates gene transcription [1] . In the presence of tissue injury, microbial invasion or oxidative stress, however, HMGB1 translocates to the cytoplasm and then into the extracellular space [1] [2] [3] . Once released into the extracellular space, HMGB1 binds to several different receptors on the cell surface and induces sterile inflammation by stimulating the synthesis and release of inflammatory cytokines [4] . The receptor for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4) are the main receptors for HMGB1 [5] . Clinically, HMGB1 is implicated in the pathogenesis of chronic inflammatory diseases such as atherosclerosis, systemic lupus erythematosus and rheumatoid arthritis as well as sepsis [1, 6] .
Lipopolysaccharide (LPS) is also an agonist of TLR4. Macrophages stimulated by LPS produce inflammatory cytokines, but on the other hand decrease TLR4 on the cell surface by endocytosis [7] and become less responsive to subsequent LPS exposure. Likewise, HMGB1 was shown to decrease cell surface TLR4 in macrophages by inducing endocytosis [8, 9] . With regard to RAGE expression following HMGB1 stimulation, the published findings are conflicting. In human microvascular endothelial cells [10] and umbilical vein endothelial cells [11] , HMGB1 was shown to increase RAGE expression. In HeLa cells transfected with RAGE [12] , HMGB1 stimulation promoted ectodomain shedding of RAGE. In a study of human embryonic kidney cells [13] , however, HMGB1 did not induce ectodomain shedding of RAGE.
Recently, we found that human aortic endothelial cells (HAECs) activated by LPS rapidly reduce TLR4 expression, and thereby decrease the responsiveness of the cells to 2 nd stimulation with LPS [14] . In contrast to macrophages, however, the loss of cell surface TLR4 in HAECs occurred through ectodomain shedding, but not by endocytosis. Thus, the mechanism by which cells regulate surface receptor expression after its ligand binding seems to be different depending on the type of cells. Plasma level of HMGB1 is elevated in the patients with diabetes mellitus [15] , chronic inflammatory diseases such as systemic lupus erythematosus and rheumatoid arthritis [16, 17] or sepsis [18] . In vitro studies have shown that HMGB1 activates aortic endothelial cells, increasing the expression of adhesion molecules and the secretion of TNF-α, IL-8 and monocyte chemotactic protein-1 [19] . By these inflammatory effects, HMGB1 is implicated in the pathogenesis of atherosclerosis of aorta and aortic aneurysm [6, 20] . In case high blood level of HMGB1 is maintained, the severity of its inflammatory effects on aorta may depend on the response of the endothelial cells lining the vessel, but so far it is not known how the cells regulate the response to continuous stimuli of HMGB1.
In the present study, we hypothesized that HAECs may downregulate the receptors for HMGB1 once activated by HMGB1, as in our previous study showing that HAECs undergo ectodomain shedding of TLR4 upon LPS activation [14] , and examined the temporal changes of RAGE and TLR4 expression in HAECs after HMGB1 treatment, and investigated the underlying mechanism.
Materials and Methods

Materials
Recombinant human HMGB1 (1690-HMB, endotoxin less than 0.10 EU/μg) was purchased from R&D Systems (Abingdon, UK). SB203580 and dimethyl sulfoxide (DMSO) were from EMD Chemicals (Darmstadt, Germany). TAPI-2 was from Cayman Chemical (Ann Arbor, MI, USA). Antibodies to human TLR4 (76B357.1: a mouse monoclonal antibody against amino acids 100 -200 of human TLR4), RAGE (sc-80652, a mouse monoclonal antibody against a truncated extracellular domain of human RAGE), p38 mitogen-activated protein kinase (p38 MAPK), ADAM10 and actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to human TLR4 (ab13556; a rabbit polyclonal antibody against amino acids 420-435 of human ) were from Life Technologies (Paisley, UK). The fluorogenic substrate, 5FAM-Ser-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-SerSer-Arg-Lys(5-TAMRA)-NH 2 , was from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). 4',6-Diamidino-2-phenylindole dihydrochloride (DAPI) and Ponceau S solution were from Sigma-Aldrich (St. Louis, MO, USA).
Cell Culture
Primary HAECs were obtained from Lonza Walkersville, Inc. (Walkersville, MD, USA) and cultured in EBM-2 endothelial growth basal medium (Lonza Walkersville, Inc.). After 3-5 passages, the cells were used for the experiments. In each experiment, the cells were seeded in equal numbers into culture plates and rested in equal volume of M199 Hank's medium (Life Technologies) containing 1% fetal bovine serum (FBS) for 24 h, and then the medium was replaced with serum-free M199 Hank's medium (Ca 2+ 1.26 mM).
Transfection of siRNA Transfection of siRNAs was performed using Lipofectamine ® Reagent (Life Technologies). Briefly, 1×10
5 cells were seeded in each 6-well plate and cultured for 24 h. To prepare siRNA-lipofectamine complexes, siRNAs (100 pmol) were incubated for 15 min with lipofectamine reagent diluted in Opti-MEM ® medium (Life Technologies) at room temperature. siRNAs were transfected by adding the siRNAlipofectamine complexes to the cell in serum-free culture medium and incubating the cells for 6 h at 37 °C in a CO 2 incubator. After siRNA transfection, the cells were cultured for 18 h in EBM-2 endothelial growth basal medium. Thereafter, the cells were rested for 24 h in M199 Hank's medium containing 1% FBS and then subjected to the experiments.
Western blot analysis
After collection of the conditioned medium, treated cells were lysed by incubation on ice for 10 min with cold lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% sodium deoxycholate, 1% NP-40, protease and phosphatase inhibitors). The lysed cells were collected using a plastic cell scraper, transferred to a microcentrifuge tube and centrifuged at 4 °C (10, 000 × g) for 20 min, and the supernatant was obtained as whole cell lysate. The cell lysates containing equal amount of protein were separated under reducing and denaturing condition by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to an Immobilon-P membrane (Merck Millipore Co., Darmstadt, Germany). The membrane was then incubated with the primary antibody, followed by washing and further incubation with horseradish peroxidase conjugated secondary antibody. Thereafter, the protein bands were visualized using an enhanced chemiluminescence agent (Luminata TM Forte Western HRP Substrate; Merck Millipore Co.). To measure RAGE and TLR4 in culture supernatant, equal volumes of conditioned medium were concentrated 30-fold using Amicon ® Ultra 10K device (Merck Millipore Co.). The samples were then incubated with 5× sample buffer for 30 min at 37
°C and subjected to immunoblot with a monoclonal antibody against an extracellular domain of RAGE or TLR4. The protein bands on the membrane were stained by Ponceau S Solution.
Immunofluorescence Staining
Cell surface expression of RAGE and TLR4 was examined by immunofluorescent staining. Treated cells were fixed with 4% paraformaldehyde for 10 min without permeabilization, and then incubated with 1% bovine serum albumin in phosphate buffered saline (PBS) for 60 min to block the nonspecific binding. Thereafter, the cells were incubated with a mouse monoclonal antibody against an extracellular domain of RAGE or TLR4 overnight at 4 °C, washed with PBS and then further incubated with FITC-conjugated antimouse IgG secondary antibody. Finally, the cells were incubated with DAPI to stain cell nuclei. RAGE or TLR4 immunoreactivity was captured using a confocal microscope (Zeiss LSM710; Carl Zeiss Microscopy, Germany).
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Metalloproteinase activity assay
The metalloproteinase activity assay was performed on cell lysates using 5-FAM-Ser-Pro-LeuAla-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Lys(5-TAMRA)-NH 2 , a fluorogenic substrate for ADAM17 and other metalloproteinases. This substrate becomes fluorescent upon cleavage of TAMRA group by the metalloproteinases. Whole cell lysates were obtained as in Western blot analysis. The fluorogenic substrate in HBSS buffer (2 µM, 50 µl) was added to 50 µl of cell lysate (20 µg protein) or cell lysis buffer (for background fluorescence) and incubated at 37 °C for 60 min. The fluorescent intensity was measured at 485 nm excitation and 535 nm emission wavelengths using a fluorescence plate reader (SPECTRmax ® GEMINI XS system; Molecular Devices, Sunnyvale, CA, USA). After subtraction of the background fluorescence obtained from the substrate alone (without cell lysate), the fluorescence intensity of the treated cells was expressed as a fold increase compared with that of the control cells.
Statistical Analysis
Data are presented as means ± SE (standard error), with n representing the number of different experiments. An analysis of variance with Scheffe's multiple-comparison test was used to determine statistically significant differences between groups. P values less than 0.05 were considered statistically significant.
Results
HMGB1 induces ectodomain shedding of RAGE and TLR4
Because TLR4 rapidly underwent ectodomain shedding in HAECs by stimulation with LPS, a ligand for TLR4, in our previous study [14] , we tested whether HMGB1 causes ectodomain shedding of RAGE and TLR4. HAECs were incubated with HMGB1 (100 ng/ ml) for up to 24 h, and the conditioned media and whole cell lysates were obtained. RAGE 3 . Involvement of p38 MAPK and metalloproteinase in HMGB1-induced ectodomain shedding of RAGE and TLR4. HAECs were preincubated with SB203580 (10 μM), TAPI-2 (10 μM) or DMSO (vehicle) for 30 min, followed by incubation with HMGB1 (100 ng/ml) for 1 h. Cell lysates and culture supernatants were analyzed by Western blotting using anti-RAGE (A), anti-TLR4 (B) or anti-actin antibodies (n=3, *p<0.05 compared with control, # p<0.05 compared with HMGB1). 
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and TLR4 in the cell lysates were examined by Western blot analysis. As shown in Fig. 1A & 2A, cellular RAGE and TLR4 began to decrease within 30 min after HMGB1 treatment and remained decreased up to 24 h. RAGE and TLR4 in the culture supernatants were detected slightly below 48 kDa and at around 48 kDa, respectively. The decrease in cellular RAGE and TLR4 after HMGB1 treatment was accompanied by an increase of N-terminal fragment of RAGE and TLR4 in culture supernatant. HMGB1-induced ectodomain shedding of RAGE and TLR4 was dose-dependent at the concentrations between 1 ~ 100 ng/ml (Fig. 1B & 2B) .
Involvement of p38 MAPK and metalloproteinase in HMGB1-induced ectodomain shedding of RAGE and TLR4
To test whether p38 MAPK and metalloproteinase are implicated in HMGB1-induced ectodomain shedding of RAGE and TLR4, we preincubated the cells with or without SB203580 (an inhibitor of p38 MAPK) or TAPI-2 (an inhibitor of ADAM family), and then stimulated them with HMGB1 for 60 min. As shown in Fig. 3 , both inhibitors attenuated HMGB1-induced ectodomain shedding of RAGE and TLR4.
HMGB1 induces a marked reduction in the expression of RAGE and TLR4 on the cell surface
Ectodomain shedding of RAGE and TLR4 should result in the reduction of RAGE and TLR4 expression on the plasma membrane. To test whether this is the case, we examined the cell surface expression of RAGE and TLR4 by immunofluorescent staining. HAECs were preincubated with or without SB203580 or TAPI-2, and then stimulated with HMGB1 for 60 min. Thereafter, the cells were immunostained for RAGE and TLR4 using a monoclonal antibody against the extracellular portion of RAGE or TLR4, without permeabilization of the cell membrane. Consistent with Western blot analysis, HMGB1 decreased RAGE and TLR4 expressions on the cell surface, while this effect of HMGB1 was inhibited by SB203580 and TAPI-2 (Fig. 4) . Fig. 4 . HMGB1 markedly reduces RAGE and TLR4 on the cell surface. HAECs were preincubated with SB203580 (10 μM), TAPI-2 (10 μM) or DMSO (vehicle) for 30 min, followed by incubation with or without HMGB1 (100 ng/ml) for 1 h. Thereafter, the cells were fixed with 4% paraformaldehyde without permeabilization, immunostained for RAGE or TLR4 using a monoclonal antibody directed against the extracellular domain of human RAGE or TLR4, and visualized with confocal microscopy. Cell nuclei were stained with DAPI. Representative images from three independent experiments are shown. Fig. 5 . ADAM17, but not ADAM10, is implicated in the ectodomain shedding of RAGE. HAECs were transfected with control-siRNA, ADAM17-siRNA (A), or ADAM10-siRNA (B) and then incubated with or without HMGB1 (100 ng/ml) for 1 h. Cell lysates and culture supernatants were analyzed by Western blotting using anti-RAGE, anti-ADAM17, anti-ADAM10 or anti-actin antibodies (n=3, *p<0.05 compared with control). Fig. 6 . ADAM17, but not ADAM10, is implicated in the ectodomain shedding of TLR4. HAECs were transfected with control-siRNA, ADAM17-siRNA (A), or ADAM10-siRNA (B) and then incubated with or without HMGB1 (100 ng/ml) for 1 h. Cell lysates and culture supernatants were analyzed by Western blotting using anti-TLR4, anti-ADAM17, anti-ADAM10 or anti-actin antibodies (n=3, *p<0.05 compared with control). 
ADAM17 is implicated in the ectodomain shedding of RAGE and TLR4
To investigate the effect of specific depletion of ADAM17, we transfected the cells with controlsiRNA or ADAM17-siRNA and then incubated the cells with or without HMGB1. As shown in Fig.  5A & 6A, depletion of ADAM17 abolished HMGB1-induced ectodomain shedding of RAGE and TLR4. Because ADAM10 is also able to cleave ectodomain portion of RAGE [12, 13, 21] and TLR4 [22] , we examined the involvement of ADAM10 in HMGB1-induced ectodomain shedding of RAGE and TLR4. As shown in Fig. 5B & 6B, HMGB1-induced ectodomain shedding of RAGE and TLR4 was not affected by ADAM10 depletion.
HMGB1 activates p38 MAPK
To determine the temporal changes of p38 MAPK activation after HMGB1 treatment, we treated the cells with HMGB1 (100 ng/ml) for different times up to 24 h. As shown in Fig. 7 , phosphorylation of p38 MAPK was increased after HMGB1 treatment and reached a peak at 60 min, and thereafter decreased.
HMGB1 activates ADAM17 through p38 MAPK pathway
We tested whether HMGB1 activates ADAM17, and whether p38 MAPK is implicated in the activation of ADAM17. ADAM17 activity was estimated by the increase in fluorescence intensity resulted from the enzymatic cleavage of the fluorogenic ADAM17 substrate. Because the substrate is not specific to ADAM17 and may also be cleaved by other ADAMs and matrix metalloproteinases, we first compared HMGB1-induced metalloprotease activity in the control cells and ADAM17-depleted cells. As shown in Fig.  8A , HMGB1 increased the metalloprotease activity about two times more than control. In contrast, siRNA depletion of ADAM17 inhibited the increase of metalloprotease activity by more than 90%. Thus, the metalloprotease activity increased after HMGB1 treatment mainly represents ADAM17 activity.
To test whether p38 MAPK is implicated in the HMGB1-induced ADAM17 activation, we preincubated the cells with or without SB203580, and stimulated them with HMGB1 for 60 min, and then measured ADAM17 activity in the cell lysates. As shown in Fig. 8B , HMGB1 increased ADAM17 activity, while this effect of HMGB1 was markedly inhibited by pretreatment with SB203580. 
HMGB1 pretreatment abolishes the response to 2 nd HMGB1 stimuli, while depletion of ADAM17 potentiates the cellular effect of HMGB1
To assess how the ectodomain shedding of RAGE and TLR4 affects the response to 2 nd HMGB1 stimuli, we measured HMGB1-induced p38 MAPK phosphorylation in HMGB1-pretreated cells and untreated cells. HMGB1 pretreatment was accomplished by being incubated with HMGB1 for 6 h. As shown in Fig. 9A, HMGB1 markedly increased p38 MAPK phosphorylation in untreated cells, but had no such effect in HMGB1-pretreated cells.
To examine how HMGB1 signaling is affected when ectodomain sheddings of RAGE and TLR4 are prohibited by depletion of ADAM17, we compared the change in p38 MAPK phosphorylation over time after HMGB1 stimulation in the control cells and ADAM17-depleted cells. HAECs were transfected with control-siRNA or ADAM17-siRNA, and then incubated with HMGB1 for 1, 6 or 24 h. Western blot revealed similar phosphorylation of p38 MAPK at 1 h after HMGB1 treatment regardless of ADAM17 depletion. In the control cells, there was a marked decline in phosphorylation of p38 MAPK over time. In the cells depleted of ADAM17, however, phosphorylation of p38 MAPK remained elevated at 6 and 24 h (Fig. 9B) .
HMGB1-induced p38 MAPK activation occurs mainly through RAGE, but not TLR4
Finally, we examined the receptor involved in HMGB1-induced p38 MAPK activation. Cells were depleted of RAGE or TLR4 by siRNA transfection and then stimulated with HMGB1. As shown in Fig. 10 , depletion of RAGE abolished HMGB1-induced p38 MAPK and ectodomain shedding of TLR4. In contrast, depletion of TLR4 did not inhibit either HMGB1-induced p38 MAPK activation or HMGB1-induced ectodomain shedding of RAGE. Fig. 9 . HMGB1 pretreatment abolishes the response to 2 nd HMGB1 stimuli, while depletion of ADAM17 potentiates the cellular effect of HMGB1. (A) HAECs were pretreated with medium alone or HMGB1 (100 ng/ml) for 6 h, washed and then stimulated for 1 h with HMGB1 (100 ng/ml). Whole cell lysates were immunoblotted with an antibody to p-p38 MAPK or p38 MAPK (n=4, *p<0.05 compared with control, **p<0.05 as compared with HMGB1-stimulated cells that received no pretreatment). (B) HAECs were transfected with control-siRNA or ADAM17-siRNA, and then incubated with HMGB1 (100 ng/ml) for 1, 6 or 24 h. Whole cell lysates were immunoblotted with an antibody to p-p38 MAPK, p38 MAPK, ADAM17 or actin (n=3, *p<0.05 compared with control-siRNA at 1 h, # p<0.05 as compared with control-siRNA at 6 h, ## p<0.05 as compared with control-siRNA at 24 h).
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Discussion
The present study demonstrates how HAECs regulate the expressions of RAGE and TLR4 after HMGB1 stimulation. Upon treatment with HMGB1, both RAGE and TLR4 rapidly underwent ectodomain shedding, which resulted in decreased responsiveness of the cells to further stimuli of HMGB1.
In human microvascular endothelial cells [10] and umbilical vein endothelial cells [11] , HMGB1 was reported to increase RAGE expression. By contrast, we found that HMGB1 treatment decreases cell surface RAGE and TLR4 in HAECs. The loss of cell surface RAGE and TLR4 was attributed to ectodomain shedding of the receptors, as evidenced by the reduction of RAGE and TLR4 in whole cell lysate with an accompanied increase in N-terminal fragment of RAGE and TLR4 in the culture supernatant. Our finding is consistent with a study showing that HMGB1 promotes ectodomain shedding of RAGE in HeLa cells transfected with RAGE [12] . Ectodomain shedding of RAGE and TLR4 abolished the activation of p38 MAPK in response to 2 nd HMGB1 stimulation. Conversely, prevention of ectodomain shedding of RAGE and TLR4 by siRNA depletion of ADAM17 resulted in prolongation of HMGB1 effects on p38 MAPK activation. The findings together indicate that HMGB1-activated HAECs become insensitive to 2 nd stimuli of HMGB1 by ectodomain shedding of the receptors. HMGB1-induced ectodomain shedding of RAGE and TLR4 was mediated by ADAM17, but not by ADAM10. In our previous studies, 1,25-dihydroxyvitamin D 3 activated ADAM10 through extracellular Ca 2+ influx [22] , while LPS activated ADAM17 through p38 MAPK pathway [14] . Activation of either ADAM10 or ADAM17 led to ectodomain shedding of TLR4. Thus, it is not strange that ADAM17 mediates HMGB1-induced ectodomain shedding of TLR4 because HMGB1 activated p38 MAPK. In case of RAGE, ADAM10, but not ADAM17, has been reported to be the major sheddase [12, 13, 21] . In the present study of HAECs, however, HMGB1 activated ADAM17, while depletion of ADAM17 markedly inhibited HMGB1-induced ectodomain shedding of RAGE. Thus, our data revealed that ADAM17 is also an important sheddase of RAGE.
HMGB1 exists in different forms of redox state and binds to different receptors on the cell surface, depending on the redox status. Within the cells, HMGB1 exists in fully reduced form [23] . After released outside of the cells, fully reduced HMGB1 acts as a ligand to RAGE or the chemokine receptor CXCR4, but does not bind to TLR4 [23] . In the extracellular space, fully reduced HMGB1 may transform into disulfide HMGB1 by formation of a disulfide bond between Cys23 and Cys45. Disulfide HMGB1 signals via TLR4 [23] . By binding to different receptors, HMGB1 has distinct cellular effects according to redox status. HMGB1 binding to RAGE activates mitogen-activated protein kinase pathways and nuclear factor-κB (NF-κB), Fig. 10 . HMGB1-induced p38 MAPK activation occurs mainly through RAGE, but not TLR4. HAECs were transfected with control-siRNA, RAGE-siRNA (A), or TLR4-siRNA (B) and then incubated with or without HMGB1 (100 ng/ml) for 1 h. Cell lysates and culture supernatants were analyzed by Western blotting using an antibody to p-p38 MAPK, p38 MAPK, TLR4, RAGE or actin (n=3, *p<0.05 compared with control). 
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and increases the expression of adhesion molecules and the secretion of chemokines [24] , while HMGB1 binding to CXCR4 potentiates chemotactic activity [23, 24] . HMGB1 binding to TLR4 activates NF-κB and increases the transcription and secretion of inflammatory mediators [24] . HMGB1 may also undergo oxidative modifications by reactive oxygen species and lose its immune function [23] . Recombinant HMGB1 used in the present study seems to include both fully reduced HMGB1 and disulfide HMGB1 because its cellular effect was shown to be mediated largely via RAGE in some studies [25, 26] , and largely via TLR4 in other studies [27, 28] . In the present study, depletion of RAGE prevented HMGB1-induced p38 MAPK activation and ectodomain shedding of TLR4, while depletion of TLR4 had little effect on HMGB1-induced p38 MAPK activation and ectodomain shedding of RAGE. Thus, RAGE, but not TLR4, was the primary receptor signaling HMGB1-induced ectodomain shedding of RAGE and TLR4 through p38 MAPK and ADAM17 activations. In our previous study [14] , LPS stimulated ADAM17-mediated ectodomain shedding of TLR4 through TLR4-p38 MAPK pathway. As HMGB1 is also a TLR4 agonist, TLR4 was anticipated to mediate this effect of HMGB1, but this was not the case. It is similar to endocytosis of TLR4 in macrophage. LPS provokes inflammatory responses of macrophage through TLR4, but also induces endocytosis of TLR4 which desensitizes the cell to 2 nd LPS challenge [7] . HMGB1 also induces endocytosis of TLR4 in macrophage, but it was shown to be mediated through RAGE, but not TLR4 [8] . Though both HMGB1 and LPS are agonists of TLR4, other studies have also shown that HMGB1 does not always induce the same cellular effects observed with LPS treatment [29, 30] . The reason is not clear, but it was assumed that both HMGB1 and LPS activate TLR4 by binding to MD-2, but to separate MD-2 epitopes, and thereby may activate different downstream signaling pathways [30] . It may also be because HMGB1 has lower affinity for TLR4 than LPS [24] .
Blood level of HMGB1 is markedly elevated in a variety of diseases. Our findings show how aortic endothelial cells regulate the response to HMGB1 in case high blood level of HMGB1 is maintained. Upon stimulation of HAECs with HMGB1, ADAM17 was also activated and decreased the receptors for HMGB1 by cleaving ectodomain of RAGE and TLR4, and thereby rendered the cells insensitive to further HMGB1 stimulation. It could be a protective mechanism preventing overstimulation from the continuous or repeated exposure to HMGB1. In line with it, ADAM17 was atheroprotective and its deficiency was shown to promote atherosclerosis in mouse models of atherosclerosis [31, 32] .
In the present study, HMGB1 was effective at 1 ~ 100 ng/ml in ectodomain shedding of RAGE and TLR4, dose-dependently. The mean serum level of HMGB1 was reported to be 1.7 ~ 40 ng/ml in normal subjects, different across the studies [33] [34] [35] . In patients with rheumatoid arthritis or systemic lupus erythematosus, HMGB1 was elevated to 71 (45-99) ng/ml (median, range) or 108 ± 48 ng/ml (mean ± standard deviation), respectively [17] . In the septic condition, HMGB1 level was shown to be higher than 100 ng/ml [36] . Thus, the concentrations of HMGB1 tested in the present study are those observed in the clinical setting.
Conclusion
Upon stimulation with HMGB1, HAECs rapidly undergo ectodomain shedding of RAGE and TLR4, and thereby become insensitive to further HMGB1 stimulation. ADAM17, activated via RAGE-p38 MAPK pathway, is implicated in the ectodomain cleavage of the receptors.
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